10X GENOMICS INC CLASS A (TXG)
Health Care · life sciences tools and services · NASDAQ
10x Genomics provides advanced single-cell and spatial biology platforms that empower researchers to decode complex biological systems at high resolution.
What 10X GENOMICS INC CLASS A does
10x Genomics is a life sciences technology company that designs and manufactures integrated solutions for analyzing biological systems at a resolution and scale that matches the complexity of biology. The company's products enable researchers to explore fundamental questions in fields like oncology, immunology, and neuroscience by providing tools for single-cell and spatial biology analysis. 10x Genomics also pursues strategic growth through acquisitions, such as Scale Biosciences and Proteintech Genomics, and is expanding into clinical and diagnostic market applications.
Themes: single-cell sequencing, spatial biology, genomics research, precision medicine, life sciences R&D
Fundamentals
- Price$77.28 as of 2026-10-08 close
- Market cap$9.9B as of 2025-12-31 (share count; price 2026-10-08)
- 1-year return+540.3% 2025-10-08 close $12.07 → 2026-10-08 close $77.28
- P/En/a negative earnings
- Net margin-6.8% FY2025, SEC XBRL
- Gross margin+69.1% FY2025, SEC XBRL
- ROE-5.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-02
- Revenue growth (YoY)-4.3% as of 2026-09-02
- Revenue CAGR (3y)+7.6% SEC XBRL
- Beta1.92 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How TXG compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TXG is not currently in any published Top 10 list. Its scores are below.
Top 10 score
Not scored for the top 10 list: it is in the most expensive tenth of the field on valuation, so it is ranked as a growth story rather than on fundamentals.
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How 10X GENOMICS INC CLASS A looks technically
10X GENOMICS INC CLASS A (TXG) is trading 115.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 284 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 4 trading days ago. It is 24.8% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 115.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +115.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $67.73 | $67.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $35.80 | $35.80 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 38 calendar days ago — the swings before that are what the structure reading is measured on | 38 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 58.7. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 284 trading days ago — a "golden cross", a bullish long-term signal | 284 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with sellers in control | 44.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 49.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($70.94 to $102.81) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 19.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $102.81 | $102.81 |
|---|---|---|
| From the 52-week high | it is 24.8% below its 52-week high (its highest price of the past year) | -24.8% |
| Above the 52-week low | it is 592.5% above its 52-week low (its lowest price of the past year) | +592.5% |
| Below the 52-week high | it is 24.8% below its highest point of the past year | 24.8% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $208.99 (set on 2021-06-29) | $208.99 |
| Given back of the 52-week move | over the past year its closes ranged ($11.47 to $97.74), and it has given back roughly a quarter of its rise from last year’s low — 24% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $41.66 to $44.43. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 23.7% |
| From the all-time high | it is 63.0% below its all-time high | -63.0% |
| Nearest price level | it is trading 69.8% above a support level at $23.34 — a price it turned at three times since 2026-01-23, most recently on 2026-05-06. Since 2024-10-08 it has 10 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -69.8% |
| All-time low | its lowest closing price on record is $6.78 (set on 2025-04-07) | $6.78 |
| Above the all-time low | it is 1039.8% above its all-time low | +1,040% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.73 between its high and its low — about 8.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.73 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $65.61 and $97.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $65.61 – $81.38 – $97.14 |
| Typical daily range (% of price) | its price moves about 8.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.7% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges above its 200-day average price (115.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.69× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.7% since the prior reading | +5.7% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 3.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -3.2% |
|---|---|---|
| Open gap | it gapped 5.1% above the previous close 35 sessions ago and has not traded back through the level it left behind at 55.63 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +5.1% |
| Gap filled | a 3.2% gap down opened on 2026-10-08 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.8 percentage points (the stock gained 17.8% while the market gained 1.0%) | +16.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 102.4 percentage points (the stock gained 106.2% while the market gained 3.8%) | +102.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 235.6 percentage points (the stock gained 253.0% while the market gained 17.5%) | +235.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 525.3 percentage points (the stock gained 540.3% while the market gained 15.0%) | +525.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold), trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, a strong downtrend, with sellers in control — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 30% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +30.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 96% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $39.47 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +95.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $71.09 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | +8.7% |
Price levels it has turned at before
TXG last closed at $77.28 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $23.34 | Support | 69.8% below the last close | turned there three times · 2026-01-23 to 2026-05-06 |
| $19.68 | Support | 74.5% below the last close | turned there twice · 2026-04-29 to 2026-05-08 |
| $17.25 | Support | 77.7% below the last close | turned there twice · 2025-01-13 to 2026-02-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $58.70.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $70.39 and $77.61 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $58.70.
This reading has stood for 23 trading days, since 2026-09-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · Analyst price target recently RAISED · beating the market · Gapped down at the open (3%+) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.32 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$62.13 range $40.00 – $90.00; median $60.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TXG
- Consensus EPS estimate-$0.02 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.00333 from -$0.01667, on 2026-09-01, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and potential for future unprofitability.","Risks associated with the timing and outcome of regulatory filings and approvals for entering clinical and diagnostic markets.","Challenges related to the successful integration of recent acquisitions."]
What changed in the latest 10-Q
AI-assisted comparison of TXG's 10-Q filed 2026-05-08 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report for fiscal year ended December 31, 2025 filed February 12, 2026; older filing references Annual Report for fiscal year ended December 31, 2024 filed February 12, 2025
- Newer filing contains comparison of three months ended March 31, 2026 and 2025; older filing contains comparison of three and nine months ended September 30, 2025 and 2024
- Newer filing includes specific revenue table for Q1 2026 vs Q1 2025 with Single Cell and Spatial breakdown for instruments and consumables
- Newer filing discloses $44.1 million of non-recurring license and royalty revenue related to patent litigation settlements in 2025 and expectation of moderate revenue increase in 2026 excluding such amounts
- Newer filing discloses inventory write-downs of $9.2 million and warranty costs decreases in Q1 2026 comparison
- Newer filing discloses $49.9 million in gains on settlements recorded in 2025 and expectation of modest operating expense decrease in 2026
- Newer filing states gross margin expected to fluctuate throughout remainder of 2026
- Newer filing contains operating expense details including $12.2 million decrease in outside legal expenses in Q1 2026
- Removed:
- Older filing's reference to Part II, Item 1A of Quarterly Report on Form 10-Q for quarter ended March 31, 2025 for Risk Factors
- Older filing's disclosure of net losses of $27.5 million and $27.3 million for three and nine months ended September 30, 2025
- Older filing's disclosure of accumulated deficit of $1.5 billion as of September 30, 2025
- Older filing's disclosure of cash and cash equivalents and marketable securities of $482.1 million
- Older filing's detailed acquisition description of Scale Biosciences transaction including dates, payment amounts, and contingent consideration details
- Older filing's revenue comparison table for three and nine months ended September 30, 2025 and 2024 with Chromium and Spatial line items
- Older filing's disclosure of $26.0 million upfront payment from Vizgen settlement recorded as $9.2 million gain on settlement and $16.8 million license and royalty revenue
- Reworded:
- Overview section: Older filing states 'Our commercial product portfolio includes our Chromium instruments and our Visium CytAssist and our Xenium Analyzer, which we refer to as "Spatial instruments,"' whereas newer filing states 'Our commercial product portfolio is made up of our Single Cell and Spatial solutions' with products listed as 'Chromium instruments, our Visium CytAssist and our Xenium Analyzer'
- Overview section: Older filing describes consumables as 'proprietary microfluidic chips, slides, reagents and other consumables for our Chromium, Visium and Xenium solutions' whereas newer filing states 'proprietary microfluidic chips, slides, reagents and other consumables for our Single Cell and Spatial solutions'
- Overview section: Older filing states 'In addition to instrument and consumable sales, we derive revenue' whereas newer filing states 'We also derive revenue' for post-warranty service contracts
- Notes:
- The two filings cover different fiscal periods (Q1 2026 vs 2025 in newer filing vs Q3 and nine months 2025 vs 2024 in older filing), making some comparisons inherently different
- The older filing text appears truncated at the end regarding Vizgen settlement description
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 28 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 10 sells ($2M) — 2 selling insiders
- Last 90 days · read to 2026-10-040 buys · 28 sells ($12M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 39 sells ($15M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-22. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TXG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
7 institutional 13F filers reported holding TXG as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 47,985,870
- Reported value $1,839,778,259
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TXG's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TXG had 16,692,300 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for TXG because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 16,692,300
- Prior settlement (shares) 16,161,855
- Reported change 3.28%
- Days to cover (reported) 7.09
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Illumina (ILMN)
- Pacific Biosciences (PACB)
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Bio-Rad Laboratories (BIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TXG vs…
10X GENOMICS INC CLASS A is found in…
TXG ranks in…
Frequently asked questions
What does 10X GENOMICS INC CLASS A (TXG) do?
10x Genomics is a life sciences technology company that designs and manufactures integrated solutions for analyzing biological systems at a resolution and scale that matches the complexity of biology. The company's products enable researchers to explore fundamental questions in fields like oncology, immunology, and neuroscience by providing tools for single-cell and spatial biology analysis.
What sector is 10X GENOMICS INC CLASS A (TXG) in?
10X GENOMICS INC CLASS A (TXG) is classified in the Health Care sector. Its industry is life sciences tools and services. It trades on NASDAQ.
Who are 10X GENOMICS INC CLASS A's (TXG) competitors?
Notable peers of 10X GENOMICS INC CLASS A (TXG) include Illumina, Pacific Biosciences, Thermo Fisher Scientific, Danaher and Bio-Rad Laboratories. This peer set is informational only — not financial advice.
Is 10X GENOMICS INC CLASS A (TXG) overbought or oversold right now?
10X GENOMICS INC CLASS A (TXG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TXG come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.